NAVI
41
-3
CF
59
3
EQT
59
2
EOG
58
2
CL
56
5
VRSK
73
5
HOG
29
-4
JNPR
46
3
VRTX
46
2
ADP
64
2
A
36
2
MRO
55
3
DE
46
3
FRT
39
-2
DTE
50
3
USB
50
2
IVZ
46
3
EXPE
88
2
MTCH
37
7
JNJ
41
2
NAVI
41
-3
CF
59
3
EQT
59
2
EOG
58
2
CL
56
5
VRSK
73
5
HOG
29
-4
JNPR
46
3
VRTX
46
2
ADP
64
2
A
36
2
MRO
55
3
DE
46
3
FRT
39
-2
DTE
50
3
USB
50
2
IVZ
46
3
EXPE
88
2
MTCH
37
7
JNJ
41
2
Financhill
Back

Akebia Therapeutics Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.25/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
59

AKBA
Akebia Therapeutics

Last Price:
1.82
Seasonality Move:
42.93%

7 Day Trial

ALL ACCESS PASS

$ 7

Start Investing Smarter Unlock Louis Navellier's Stock Grader for free

Louis' clients have paid up to $30,000 for these insights - now you can try it at no cost.

Akebia Therapeutics Price Quote

$1.82
+0.03 (+1.68%)
(Updated: November 21, 2024 at 2:35 PM ET)

Akebia Therapeutics Key Stats

Buy
59
Akebia Therapeutics (AKBA) is a Buy
Day range:
$1.78 - $1.82
52-week range:
$0.80 - $2.48
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
2.16
P/B ratio:
0%
Volume:
1.1M
Avg. volume:
2.2M
1-year change:
75.49%
Market cap:
$392.7M
Revenue:
$194.6M
EPS:
$-0.23

How Much Does Akebia Therapeutics Make?

Is Akebia Therapeutics Growing As A Company?

  • What Is Akebia Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.11%
  • What Is Akebia Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Akebia Therapeutics Stock Price Performance

What Is Akebia Therapeutics 52-Week High & Low?

Akebia Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Akebia Therapeutics?

Is Akebia Therapeutics Cash Flow Positive?

  • What Is AKBA Cash Flow From Operations?
    Cash flow from operations (TTM) is -$38.5M
  • What Is Akebia Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $26M
  • What Is Akebia Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$31K

Akebia Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    AKBA return on invested capital is -9553.8%
  • What Is Akebia Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -20.36%
  • What Is AKBA Return On Equity?
    ROE is a measure of profitability and is 0%

Akebia Therapeutics Earnings Date & Stock Price

Akebia Therapeutics Competitors

  • Who Are Akebia Therapeutics's Competitors?
    Below is a list of companies who compete with Akebia Therapeutics or are related in some way:
    • Bioventus Inc (BVS)
    • Corcept Therapeutics Inc (CORT)
    • Eli Lilly and Co (LLY)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Palatin Technologies Inc (PTN)

Akebia Therapeutics Dividend Yield

Akebia Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -100%
Revenue: -10.98% -15.9%

Analyst Recommendations

Buy Recommendations: 1
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 5.50
Upside from Last Price: 207.26%

Major Shareholders

  • How many AKBA shares are owned by institutional investors?
    95M AKBA shares are owned by institutional investors
  • How many AKBA shares are owned by insiders?
    7.9M AKBA shares are owned by insiders